Syndax Announces Participation in June Investor Conferences
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on innovative cancer therapies, has announced its participation in two major upcoming investor conferences in June 2025. CEO Michael A. Metzger and the management team will engage in fireside chats at the Jefferies Global Healthcare Conference on June 5 at 1:25 p.m. ET and the Goldman Sachs 46th Annual Global Healthcare Conference on June 11 at 2:00 p.m. ET. Both presentations will be available via live webcast on the company's website investor section, with replays accessible for a limited time.
Syndax Pharmaceuticals (NASDAQ: SNDX), un'azienda biofarmaceutica in fase commerciale focalizzata su terapie innovative contro il cancro, ha annunciato la sua partecipazione a due importanti conferenze per investitori previste per giugno 2025. Il CEO Michael A. Metzger e il team di gestione parteciperanno a colloqui informali durante la Jefferies Global Healthcare Conference il 5 giugno alle 13:25 ET e alla Goldman Sachs 46th Annual Global Healthcare Conference l'11 giugno alle 14:00 ET. Entrambe le presentazioni saranno trasmesse in diretta streaming nella sezione investitori del sito web dell'azienda, con la possibilità di rivederle per un periodo limitato.
Syndax Pharmaceuticals (NASDAQ: SNDX), una empresa biofarmacéutica en etapa comercial centrada en terapias innovadoras contra el cáncer, ha anunciado su participación en dos importantes conferencias para inversores que se llevarán a cabo en junio de 2025. El CEO Michael A. Metzger y el equipo directivo participarán en charlas informales en la Jefferies Global Healthcare Conference el 5 de junio a la 1:25 p.m. ET y en la Goldman Sachs 46th Annual Global Healthcare Conference el 11 de junio a las 2:00 p.m. ET. Ambas presentaciones estarán disponibles vía webcast en vivo en la sección de inversores del sitio web de la compañía, con repeticiones accesibles por un tiempo limitado.
Syndax Pharmaceuticals (NASDAQ: SNDX)는 혁신적인 암 치료제에 주력하는 상업 단계의 바이오제약 회사로, 2025년 6월에 개최되는 두 개의 주요 투자자 컨퍼런스에 참가할 예정임을 발표했습니다. CEO 마이클 A. 메츠거와 경영진은 6월 5일 오후 1시 25분(동부 시간)에 열리는 Jefferies Global Healthcare Conference와 6월 11일 오후 2시(동부 시간)에 열리는 Goldman Sachs 46th Annual Global Healthcare Conference에서 대담에 참여할 예정입니다. 두 발표 모두 회사 웹사이트 투자자 섹션에서 라이브 웹캐스트로 제공되며, 제한된 기간 동안 다시보기 서비스도 이용할 수 있습니다.
Syndax Pharmaceuticals (NASDAQ: SNDX), une société biopharmaceutique en phase commerciale axée sur des thérapies innovantes contre le cancer, a annoncé sa participation à deux grandes conférences pour investisseurs prévues en juin 2025. Le PDG Michael A. Metzger et l'équipe de direction participeront à des discussions informelles lors de la Jefferies Global Healthcare Conference le 5 juin à 13h25 ET et lors de la Goldman Sachs 46th Annual Global Healthcare Conference le 11 juin à 14h00 ET. Les deux présentations seront disponibles en webdiffusion en direct dans la section investisseurs du site internet de la société, avec des rediffusions accessibles pour une durée limitée.
Syndax Pharmaceuticals (NASDAQ: SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf innovative Krebstherapien spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Juni 2025 angekündigt. CEO Michael A. Metzger und das Managementteam werden am 5. Juni um 13:25 Uhr ET an einem Fireside-Chat auf der Jefferies Global Healthcare Conference und am 11. Juni um 14:00 Uhr ET auf der Goldman Sachs 46th Annual Global Healthcare Conference teilnehmen. Beide Präsentationen werden live per Webcast im Investor-Bereich der Unternehmenswebseite verfügbar sein, mit Wiedergaben, die für eine begrenzte Zeit abrufbar sind.
- None.
- None.
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
- Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.
- Goldman Sachs 46th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 11, 2025, at 2:00 p.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
When is Syndax Pharmaceuticals (SNDX) presenting at the Jefferies Global Healthcare Conference 2025?
What time is SNDX's presentation at the Goldman Sachs Healthcare Conference 2025?
Who will represent Syndax Pharmaceuticals at the June 2025 investor conferences?
Where can investors watch Syndax's (SNDX) June 2025 conference presentations?
